Ridolfo A S, Thompkins L, Bechtol L D, Carmichael R H
J Pharm Sci. 1979 Jul;68(7):850-2. doi: 10.1002/jps.2600680716.
The particle-size effect of benoxaprofen, a new nonsteroidal anti-inflammatory agent, on the in vitro dissolution rate and oral absorption in humans was evaluated. Ten normal subjects participated in a randomized crossover-designed absorption study with two sieved particle-size formulations: one with crystals larger than 60 mesh (mean equivalent spherical diameter = 640 micron) and the other with crystals smaller than 100 mesh (mean equivalent spherical diameter = 67 micron). Plasma drug concentrations and urinary drug excretion were used to determine the relative absorption of the two formulations. The standard USP procedure was used for the dissolution study. Particle size had a dramatic effect on both the in vitro drug dissolution and its oral absorption in humans. In vitro, the smaller crystals dissolved more rapidly and more efficiently than the larger crystals. In vivo, the smaller crystals produced higher plasma concentrations, more rapid peak concentration attainment, and more drug excreted in the urine.
对一种新型非甾体抗炎药贝诺洛芬的粒径效应进行了评估,考察其对体外溶出速率及人体口服吸收的影响。10名正常受试者参与了一项随机交叉设计的吸收研究,该研究采用了两种经筛分的不同粒径制剂:一种是晶体大于60目(平均等效球径 = 640微米),另一种是晶体小于100目(平均等效球径 = 67微米)。采用血浆药物浓度和尿药排泄量来确定两种制剂的相对吸收情况。溶出度研究采用美国药典标准方法。粒径对体外药物溶出及人体口服吸收均有显著影响。体外实验中,较小晶体的溶解速度比大晶体更快且更有效。体内实验中,较小晶体产生更高的血浆浓度,达到峰浓度的速度更快,且尿中排泄的药物更多。